Insiders · PHIO

PHIO insider transactions

Phio Pharmaceuticals Corp. (PHIO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

PHIO insiders

Everyone who has filed a Form 4 or 5 at Phio Pharmaceuticals Corp., latest first. Follow anyone to get their next filing.

• Ronald Todd PlottDirector+$27.5K
• Robert J BittermanChairman, Pres. & CEO, Director+$76.1K
• Lisa Cabott CarsonChief Financial Officer
• Patricia A BradfordDirector+$12.4K
• Curtis LockshinDirector
• Jonathan E FreemanDirector
• David H DemingDirector
• Robert L FerraraDirector+$21.8K
• Robert M. InfarinatoVP, CFO
• Caitlin KontulisSecretary & VP Finance & Admin
• Geert CauwenberghDirector
• Gerrit DispersynOfficer, Director+$22.4K
• H. Paul DormanDirector

Recent Form 3, 4, and 5 filings for PHIO

• 36d
  Director Plott Ronald Todd bought $10,350 worth of shares (10,000 units at $1.03), increasing direct ownership by 31% to 42,000 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 37d
  Chairman, Pres. & CEO Bitterman Robert J was granted 400,000 shares, increasing direct ownership by 110% to 764,871 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 37d
  Chief Financial Officer Carson Lisa Cabott was granted 108,000 shares, increasing direct ownership by 133% to 189,112 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 37d
  Director Plott Ronald Todd was granted 17,000 shares, increasing direct ownership by 113% to 32,000 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 41d
  SEC Form 4 filed by Phio Pharmaceuticals Corp.

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 43d
  Chairman, Pres. & CEO Bitterman Robert J bought $2,058 worth of shares (2,000 units at $1.03), increasing direct ownership by 0.55% to 364,871 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 50d
  Director Bradford Patricia A bought $12,360 worth of shares (12,000 units at $1.03), increasing direct ownership by 26% to 57,651 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 51d
  Chairman, Pres. & CEO Bitterman Robert J covered exercise/tax liability with 68,550 shares, decreasing direct ownership by 16% to 362,871 units (SEC Form 4) to satisfy withholding tax

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 51d
  Chief Financial Officer Carson Lisa Cabott covered exercise/tax liability with 12,888 shares, decreasing direct ownership by 14% to 81,112 units (SEC Form 4) (withholding obligation)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 78d
  Director Plott Ronald Todd bought $17,100 worth of shares (15,000 units at $1.14) (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 78d
  Chairman, Pres. & CEO Bitterman Robert J bought $10,600 worth of shares (10,000 units at $1.06), increasing direct ownership by 2% to 431,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 98d
  SEC Form 3 filed by new insider Plott Ronald Todd

  3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 129d
  Chairman, Pres. & CEO Bitterman Robert J bought $9,900 worth of shares (10,000 units at $0.99), increasing direct ownership by 2% to 421,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 273d
  Director Lockshin Curtis was granted 16,600 shares, increasing direct ownership by 89% to 35,155 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 273d
  Director Freeman Jonathan E was granted 16,600 shares, increasing direct ownership by 103% to 32,655 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 273d
  Director Deming David H was granted 23,800 shares, increasing direct ownership by 170% to 37,800 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 273d
  Chief Financial Officer Carson Lisa Cabott was granted 47,000 shares, increasing direct ownership by 100% to 94,000 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 273d
  Director Bradford Patricia A was granted 18,500 shares, increasing direct ownership by 68% to 45,651 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 273d
  Chairman, Pres. & CEO Bitterman Robert J was granted 120,000 shares, increasing direct ownership by 41% to 411,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 307d
  Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 312d
  Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 346d
  Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 351d
  Chairman, Pres. & CEO Bitterman Robert J bought $6,350 worth of shares (5,000 units at $1.27), increasing direct ownership by 2% to 276,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 416d
  Amendment: Director Ferrara Robert L was granted 23,100 shares, increasing direct ownership by 147% to 38,766 units (SEC Form 4)

  4/A - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 417d
  Director Deming David H was granted 14,000 shares (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 417d
  Director Lockshin Curtis was granted 16,200 shares, increasing direct ownership by 688% to 18,555 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 417d
  Director Freeman Jonathan E was granted 14,700 shares, increasing direct ownership by 1,085% to 16,055 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 417d
  Director Ferrara Robert L was granted 23,000 shares, increasing direct ownership by 147% to 38,666 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 417d
  VP, Finance and Administration Carson Lisa Cabott was granted 47,000 shares (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 417d
  Director Bradford Patricia A was granted 18,800 shares, increasing direct ownership by 225% to 27,151 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 417d
  Chairman, Pres. & CEO Bitterman Robert J covered exercise/tax liability with 4,111 shares and was granted 250,000 shares, increasing direct ownership by 963% to 271,421 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 505d
  SEC Form 3 filed by new insider Carson Lisa Cabott

  3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 512d
  Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 512d
  Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 513d
  Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 532d
  Chairman, Pres & CEO Bitterman Robert J bought $7,446 worth of shares (4,200 units at $1.77), increasing direct ownership by 22% to 23,649 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 533d
  Director Ferrara Robert L bought $4,550 worth of shares (2,500 units at $1.82), increasing direct ownership by 23% to 13,166 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 611d
  SEC Form 3 filed by new insider Deming David H

  3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 783d
  VP, CFO Infarinato Robert M. was granted 3,000 shares, increasing direct ownership by 38% to 11,000 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 783d
  Director Freeman Jonathan E was granted 1,000 shares (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 783d
  Chairman, Pres & CEO Bitterman Robert J was granted 15,500 shares, increasing direct ownership by 665% to 17,832 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 784d
  Director Lockshin Curtis was granted 2,000 shares (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 784d
  Director Ferrara Robert L was granted 10,000 shares (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 784d
  Director Bradford Patricia A was granted 8,000 shares (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 812d
  VP, Chief Financial Officer Infarinato Robert M. was granted 8,000 shares (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 819d
  SEC Form 3 filed by new insider Infarinato Robert M.

  3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 877d
  President & CEO Bitterman Robert J bought $740 worth of shares (1,000 units at $0.74), increasing direct ownership by 5% to 20,990 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 878d
  President & CEO Bitterman Robert J bought $750 worth of shares (1,000 units at $0.75), increasing direct ownership by 5% to 19,990 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 975d
  Kontulis Caitlin covered exercise/tax liability with 335 shares, decreasing direct ownership by 3% to 10,643 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 982d
  Bitterman Robert J bought $2,275 worth of shares (2,500 units at $0.91), increasing direct ownership by 15% to 18,990 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 987d
  Bitterman Robert J covered exercise/tax liability with 1,804 shares, decreasing direct ownership by 10% to 16,490 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 989d
  Kontulis Caitlin covered exercise/tax liability with 1,181 shares, decreasing direct ownership by 10% to 10,978 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1129d
  Bitterman Robert J covered exercise/tax liability with 917 shares, decreasing direct ownership by 5% to 18,294 units (SEC Form 4)

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1219d
  SEC Form 4 filed by Bitterman Robert J

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1239d
  SEC Form 4 filed by Ferrara Robert L

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1352d
  SEC Form 4: Lockshin Curtis was granted 1,500 shares, increasing direct ownership by 88% to 3,197 units

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1352d
  SEC Form 4: Freeman Jonathan E was granted 1,500 shares, increasing direct ownership by 88% to 3,197 units

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1352d
  SEC Form 4: Ferrara Robert L was granted 1,500 shares, increasing direct ownership by 60% to 4,000 units

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1352d
  SEC Form 4: Cauwenbergh Geert was granted 1,500 shares, increasing direct ownership by 55% to 4,235 units

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
• 1352d
  SEC Form 4: Bradford Patricia A was granted 1,500 shares, increasing direct ownership by 90% to 3,167 units

  4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)